Alectinib in Crizotinib-Refractory ALK-Rearranged Non-Small-Cell Lung Cancer: A Phase II Global Study.

By S. Ou, J. Ahn, L. De Petris, R. Govindan, Jie Yang, B. Hughes, H. Léna, D. Moro-Sibilot, A. Bearz, Santiago Viteri Ramírez and 8 more. Journal of Clinical Oncology, 2016

601 citations recorded by the source corpus.

Subfields: Oncology, Pulmonary and Respiratory Medicine

View Paper: https://www.semanticscholar.org/paper/b4515f4861167184f1cdc552ec4468fc9e682c8d

Citations in the corpus

• Brigatinib versus Crizotinib in ALK‐Positive Non–Small‐Cell Lung Cancer (2018, unknown): “Decreased appetite 10 (7) 1 (1) 27 (20) 4 (3)”